Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Philogen SpA ( (IT:PHIL) ) just unveiled an update.
Philogen has decided to withdraw its marketing authorization application for Nidlegy™, a treatment for locally advanced melanoma, from the European Medicines Agency due to delays in providing necessary data. Despite this setback, Philogen remains confident in Nidlegy™’s efficacy and safety profile, and plans to resubmit the application with updated data to make the treatment available for both melanoma and non-melanoma skin cancer patients.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company focused on developing innovative pharmaceuticals for cancer treatment. The company specializes in using ligands to deliver potent payloads to tumors while sparing healthy tissues. Philogen is headquartered in Siena, Italy, with a research center in Zurich, Switzerland, and is also involved in developing treatments for chronic and debilitating conditions.
Average Trading Volume: 17,771
Technical Sentiment Signal: Buy
Current Market Cap: €777.9M
Find detailed analytics on PHIL stock on TipRanks’ Stock Analysis page.